The vaccine adjuvant monophosphoryl lipid A is a partial agonist of TLR4

被引：0
|
作者：
Haro, Veronica Mata [1 ]
Casella, Carolyn R. [1 ]
Cekic, Caglar [1 ]
Chilton, Paula M. [1 ]
Mitchell, Thomas C. [1 ]
机构：
[1] Univ Louisville, Inst Cellular Therapeut, Louisville, KY 40202 USA
来源：
JOURNAL OF IMMUNOLOGY | 2006年 / 176卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：S176 / S176
页数：1
相关论文
共 50 条
  • [41] Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 Agonist, Promotes Potent Systemic and Mucosal Responses to Intranasal Immunization with HIVgp140
    Arias, Mauricio A.
    Van Roey, Griet A.
    Tregoning, John S.
    Moutaftsi, Magdalini
    Coler, Rhea N.
    Windish, Hillarie P.
    Reed, Steven G.
    Carter, Darrick
    Shattock, Robin J.
    PLOS ONE, 2012, 7 (07):
  • [42] LPS mimotopes: A novel class of TLR4 agonist
    Shanmugam, Arulkumaran
    Rajoria, Shilpi
    George, Andrea
    Mittelman, Abraham
    Tiwari, Raj K.
    Suriano, Robert
    CANCER RESEARCH, 2011, 71
  • [43] TLR4 Ligands Lipopolysaccharide and Monophosphoryl Lipid A Differentially Regulate Effector and Memory CD8+ T Cell Differentiation
    Cui, Weiguo
    Joshi, Nikhil S.
    Liu, Ying
    Meng, Hailong
    Kleinstein, Steven H.
    Kaech, Susan M.
    JOURNAL OF IMMUNOLOGY, 2014, 192 (09): : 4221 - 4232
  • [44] Bordetella pertussis monophosphoryl lipid A as adjuvant for inactivated split virion influenza vaccine in mice
    Quintilio, Wagner
    Kubrusly, Flavia S.
    Iourtov, Dmitri
    Miyaki, Cosue
    Sakauchi, Maria Aparecida
    Lucio, Fernanda
    Dias, Sandra de Cassia
    Takata, Celia S.
    Miyaji, Eliane N.
    Higashi, Hisako G.
    Leite, Luciana C. C.
    Raw, Isaias
    VACCINE, 2009, 27 (31) : 4219 - 4224
  • [45] Ceramide as a TLR4 agonist;: a putative signalling intermediate between sphingolipid receptors for microbial ligands and TLR4
    Fischer, Hans
    Ellstrom, Patrik
    Ekstrom, Kristina
    Gustafsson, Lotta
    Gustafsson, Mattias
    Svanborg, Catharina
    CELLULAR MICROBIOLOGY, 2007, 9 (05) : 1239 - 1251
  • [46] A novel defined TLR3 agonist as an effective vaccine adjuvant
    Ko, Kwang Hyun
    Cha, Seung Bin
    Lee, Seung-Hwan
    Bae, Hyun Shik
    Ham, Chul Soo
    Lee, Min-Gyu
    Kim, Dong-Ho
    Han, Seung Hyun
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [47] Development of a New Vaccine Adjuvant System Based on the Combination of the Synthetic TLR4 Agonist FP20 and a Synthetic QS-21 Variant
    Shaik, Mohammed Monsoor
    Pasco, Samuel
    Romerio, Alessio
    Pifferi, Carlo
    Sesana, Silvia
    Re, Francesca
    Bezuidenhout, Charl Xavier
    Bracco, Silvia
    Fernandez-Tejada, Alberto
    Anguita, Juan
    Peri, Francesco
    JOURNAL OF MEDICINAL CHEMISTRY, 2024,
  • [48] Methylglycol chitosan and a synthetic TLR4 agonist enhance immune responses to influenza vaccine administered sublingually
    Spinner, Justin L.
    Oberoi, Hardeep S.
    Yorgensen, Yvonne M.
    Poirier, Danielle S.
    Burkhart, David J.
    Plante, Martin
    Evans, Jay T.
    VACCINE, 2015, 33 (43) : 5845 - 5853
  • [49] Molecular Signatures of a TLR4 Agonist-Adjuvanted HIV-1 Vaccine Candidate in Humans
    Anderson, Jenna
    Olafsdottir, Thorunn A.
    Kratochvil, Sven
    McKay, Paul F.
    Ostensson, Malin
    Persson, Josefine
    Shattock, Robin J.
    Harandi, Ali M.
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [50] Synthesis of a TLR4 Agonist-Carbohydrate Antigen Conjugate As A Self-Adjuvanting Cancer Vaccine
    Lewicky, Jordan D.
    Ulanova, Marina
    Jiang, Zi-Hua
    CHEMISTRYSELECT, 2016, 1 (05): : 906 - 910
12345